Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients

Figure 1 Lysine specific demethylase 1 expression in hepatocellular carcinoma and adjacent non-neoplastic liver tissues. A: High expression of lysine specific demethylase 1 (LSD1) in hepatocellular carcinoma (HCC) samples; B: Low expression of LSD1 in HCC samples (original magnification, 200×).

Figure 2 Increased lysine specific demethylase 1 protein and mRNA levels in hepatocellular carcinoma with different tumor node metastasis stages and adjacent non-neoplastic liver tissues. A: Representative Western blotting of lysine specific demethylase 1 (LSD1) protein levels in hepatocellular carcinoma (HCC) tissues (T) and adjacent non-neoplastic liver tissues (N); B: Semiquantitative Western blotting showed that the expression levels of LSD1 protein were significantly higher than those in adjacent non-neoplastic liver tissues (P < 0.01). Additionally, the expression levels of LSD1 protein increased with ascending tumor node metastasis (TNM) stages. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. P values, mean and SD were given (t test); C: Quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay showed significantly increased LSD1 mRNA levels in HCC tissues compared with adjacent non-neoplastic liver tissues (P < 0.01). Additionally, the expression levels of LSD1 mRNA were increased with ascending tumor TNM stages. GAPDH was used as the internal control. P values, mean and SD were given (Mann-Whitney test).

Figure 3 Kaplan-Meier survival curves for lysine specific demethylase 1 expression in hepatocellular carcinoma patients. A: The hepatocellular carcinoma patients with high lysine specific demethylase 1 (LSD1) expression showed significantly shorter disease-free survival (P < 0.001); B: Overall survival (P < 0.001) rates than those with low LSD1 expression.